Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Phase 1

Completed

Conditions: Bioequivalence
Fixed Dose Combination Tablets
Healthy Male and Female Subjects

Interventions: Drug: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)
Drug: dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)
Drug: dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)
Drug: dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)

First Posted Date: 2015-12-22

Last Posted Date: 2018-03-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 80

Registration Number: NCT02637037

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects

Phase 1

Completed

Conditions: Cardiovascular Disease
Healthy Male Subjects

Interventions: Drug: AZD5718 placebo oral suspension
Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)
Drug: AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)
Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)

First Posted Date: 2015-12-16

Last Posted Date: 2019-03-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 96

Registration Number: NCT02632526

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumours

Interventions: Drug: AZD1775
Drug: MEDI4736

First Posted Date: 2015-11-30

Last Posted Date: 2025-05-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 56

Registration Number: NCT02617277

Locations: 🇺🇸
Research Site, Nashville, Tennessee, United States

"Me and My Heart" Study

Completed

Conditions: Acute Coronary Syndrome

Interventions: Device: Active group with MEMS
Device: Control group without MEMS
Device: Active group without MEMS
Device: Control group with MEMS

First Posted Date: 2015-11-26

Last Posted Date: 2020-06-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 677

Registration Number: NCT02615704

Locations: 🇩🇪
Research Site, Wuppertal, Germany

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

Phase 1

Active, not recruiting

Conditions: Non-alcoholic Steatohepatitis (NASH)

Interventions: Drug: AZD4076
Drug: Placebo

First Posted Date: 2015-11-24

Last Posted Date: 2025-06-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 40

Registration Number: NCT02612662

Locations: 🇺🇸
Research Site, Brooklyn, Maryland, United States

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Phase 1

Completed

Conditions: Locally Advanced Solid Tumours
Metastatic Solid Tumours
Ovarian Cancer

Interventions: Drug: AZD1775

First Posted Date: 2015-11-20

Last Posted Date: 2023-07-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 62

Registration Number: NCT02610075

Locations: 🇺🇸
Research Site, Nashville, Tennessee, United States

Proton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux Disease.

Completed

Conditions: Patients With Typical Symptoms of GERD (GERD Q >= 8)

First Posted Date: 2015-11-17

Last Posted Date: 2017-11-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 1000

Registration Number: NCT02606851

Locations: 🇨🇳
Research Site, Xining, China

Egypt Hypertension Study

Completed

Conditions: Different Classes of the Antihypertensive Treatment

First Posted Date: 2015-11-13

Last Posted Date: 2019-11-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 1500

Registration Number: NCT02604771

Locations: 🇪🇬
Research Site, Egypt, Cairo, Egypt

A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects

Phase 1

Completed

Conditions: Safety
Pharmacokinetics
Healthy Subjects

Interventions: Drug: Anifrolumab placebo SC injection (300mg)
Drug: Anifrolumab placebo IV infusion (300mg)
Drug: Anifrolumab SC infusion (600mg)
Drug: Anifrolumab placebo SC infusion (600mg)
Drug: Anifrolumab SC injection (300mg)
Drug: Anifrolumab IV infusion (300mg)

First Posted Date: 2015-11-10

Last Posted Date: 2019-02-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 30

Registration Number: NCT02601625

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer

Phase 1

Completed

Conditions: Advanced and Metastatic Breast Cancer

Interventions: Drug: AZD2014
Drug: Palbociclib
Drug: Fulvestrant

First Posted Date: 2015-11-09

Last Posted Date: 2024-06-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 54

Registration Number: NCT02599714

Locations: 🇬🇧
Research Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy